Vicore Pharma
A clinical-stage pharmaceutical company dedicated to creating life-changing treatments for severe lung diseases and related indications.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | SEK782m | Post IPO Equity |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (51 %) | 253 % | 444 % | - | - | - | 2186119 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (4400 %) | (2638 %) | (783 %) | - | - | (5110511 %) | (176 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2693 %) | (2638 %) | (767 %) | - | - | (6218622 %) | (154 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Vicore Pharma is a biopharmaceutical company headquartered in Stockholm, Sweden, specializing in the development of innovative therapies for rare lung diseases, particularly idiopathic pulmonary fibrosis (IPF). The company focuses on Angiotensin II Type 2 Receptor Agonists (ATRAGs), a novel class of drugs that target the underlying fibrosis by stimulating the protective arm of the renin-angiotensin system. Vicore Pharma's core product, buloxibutid, has shown promising results in improving lung function over 36 weeks in patients with IPF, as demonstrated in their Phase 2a AIR trial. The company operates in the biopharmaceutical market, serving patients with rare lung diseases and collaborating with healthcare providers and research institutions. Vicore Pharma generates revenue through the development and commercialization of its proprietary therapies, as well as through strategic partnerships and licensing agreements. The company aims to address unmet medical needs and improve the quality of life for patients suffering from debilitating lung conditions.
Keywords: biopharmaceutical, rare lung diseases, idiopathic pulmonary fibrosis, ATRAGs, buloxibutid, renin-angiotensin system, lung function, Phase 2a trial, healthcare providers, strategic partnerships.